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Neuromodulation has taken a foothold in the landscape of surgical treatment for
medically refractory epilepsies and offers additional surgical treatment options for patients who are not candidates for resective/ablative surgery. Approximately one third of
patients with epilepsy suffer with medication-refractory epilepsy. A persistent underuse of
epilepsy surgery exists. Neuromodulation treatments including deep brain stimulation
(DBS) expand the surgical options for patients with epilepsy and provide options for
patients who are not candidates for resective surgery. DBS of the bilateral anterior nucleus
of the thalamus is an Food and Drug Administration-approved, safe, and efﬁcacious
treatment option for patients with refractory focal epilepsy. The purpose of this consensus
position statement is to summarize evidence, provide recommendations, and identify
indications and populations for future investigation in DBS for epilepsy. The recommendations of the American Society of Functional and Stereotactic Neurosurgeons are
based on several randomized and blinded clinical trials with high-quality data to support
the use of DBS to the anterior nucleus of the thalamus for the treatment of refractory focalonset seizures.
KEY WORDS: Deep brain stimulation, Thalamus, Epilepsy, Neuromodulation
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EXECUTIVE SUMMARY
Background and Purpose of Statement
· Neuromodulation has taken a foothold in the
landscape of surgical treatment for medically
refractory epilepsies and offers additional
surgical treatment options for patients who are
not candidates for resective/ablative surgery.
· Deep brain stimulation (DBS) of the bilateral
anterior nucleus of the thalamus (ANT) is an
Food and Drug Administration (FDA)approved, safe, and efﬁcacious treatment option for patients with refractory focal epilepsy.
· Our goal is to summarize evidence, provide recommendations, and identify indications and populations for future investigation in DBS for epilepsy.
Importance of the American Society of
Stereotactic and Functional
Neurosurgery Statement
· Stereotactic and functional neurosurgeons are
involved in the care of patients with medically
refractory epilepsies and are domain-speciﬁc
experts in the procedures (and related risks,
beneﬁts, and alternatives) of DBS.
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· Clinical practice parameter published jointly
by the American Academy of Neurology,
American Epilepsy Society, and American
Association of Neurological Surgeons (2003)
recommends early referral of patients with
medically refractory epilepsy to a tertiary epilepsy center for surgical evaluation.
Importance and Underutilization of
Epilepsy Surgery in the Treatment of
Refractory Epilepsy
· Approximately one third of patients with epilepsy suffer with medication-refractory epilepsy.
· A persistent underuse of epilepsy surgery
exists.
· Neuromodulation treatments including DBS
expand the surgical options for patients with
epilepsy and provide options for patients who
are not candidates for resective surgery.
Indications for DBS for
Medication-Refractory Epilepsies
· Conﬁrmed diagnosis of epilepsy by an epileptologist with focal-onset seizures, with or
without generalization;
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· Failure to adequately control seizures after 2 (or more) appropriate and adequately dosed antiseizure medications;
· Either partial-onset seizures with a localized onset in a region
not amenable to resection or after failed resective surgery or
focal-onset seizures with a distributed or unclear onset zone.
Contraindications With DBS for Medically
Refractory Epilepsies
· Patients who are anticipated to require transcranial magnetic
stimulation (TMS) therapy in the future because TMS therapy
is contraindicated for patients with an implanted DBS system.
· Patients who are unable or do not have the necessary assistance
to properly operate the DBS therapy, patient programmer or
charging system where applicable.
· Patients in whom the risk of an intracranial surgical procedure
and/or general anesthesia is unacceptable because of an underlying medical condition.
Support for Recommendations
Several randomized and blinded clinical trials support the use of
DBS for the treatment of refractory epilepsy with high-quality
data to support the use of DBS to the ANT for the treatment of
refractory focal-onset seizures.

SUPPORTING LITERATURE
Background
Epilepsies are common, chronic, heterogenous, and debilitating syndromes. The lifetime prevalence of epilepsy is 1%
worldwide,1 and 30% to 40% of patients suffer medically refractory epilepsy (as deﬁned as resistant to 2 or more appropriate
ﬁrst-line and patient-tolerated antiseizure medications).2,3 Epilepsies presenting with partial/focal-onset seizures, especially those
associated with temporal lobe epilepsy, are over-represented
among drug-resistant epilepsy.4 The sudden and unpredictable
occurrence of seizures leads to signiﬁcant morbidity, mortality,
and impairment to quality of life.5,6 Surgical treatment should be
considered early in medically refractory epilepsy.7
Surgical Treatment of Medically Refractory Epilepsy
The surgical treatment paradigm for epilepsy syndromes is ﬁrst
to aim for complete or partial resection or ablation of the seizureonset zone if this can be performed safely without signiﬁcant
neurological or neuropsychological impairment. Anterior temporal lobectomy has been shown to be highly efﬁcacious for
temporal lobe epilepsy in a prospective randomized controlled
trial (RCT),8 with 58% freedom from seizures with an altered
level of consciousness (Engel I status) after 1 year in the surgical
group compared with 8% with continuous medical therapy.
Long-term follow-up suggests that7 50% to 60% of patients with
temporal lobe epilepsy obtain Engel I status,9,10 whereas resective
outcomes after extratemporal-onset zones are less favorable at
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40% to 50%.11-13 Recently, laser interstitial thermocoagulation
therapy has been used as an ablative strategy for mesial temporal
epilepsy (50%-60% 1-year seizure freedom14,15) and epilepsies
originating from deep onset focus (ie, hypothalamic hamartomas
and deep focal cortical dysplasias).16,17
For people suffering from medically refractory epilepsy who are
not candidates for resection or ablation, neuromodulation is an
established treatment. Large randomized studies of vagus nerve
stimulation (VNS) found 24.5% to 28% reduction in seizure
frequency18,19; long-term follow-up showed that 44.1% of patients had >50% long-term reduction in seizure frequency.20
Responsive neurostimulation (RNS), which is distinct because of
its closed-loop “response” to an electrographically detected seizure, has been shown in the pivotal RCT to have a 37.9% decrease
in seizure frequency in a 12-week blinded period.21 Long-term
follow-up showed a 53% seizure reduction after a 2-year openlabel period,22 with long-lasting efﬁcacy and even progressive
median seizure reduction (75% reduction at 9 years).23 Of note,
for patients with a VNS or RNS device currently in place, that
device does not need to be removed before a DBS system is
placed.24
ANT—DBS
The ANT is composed of 3 subnuclei and is a highly connected
key node in several networks, including the Papez circuit, through
connections to the subiculum, retrosplenium, mammillary bodies, orbitofrontal prefrontal cortex, and anterior cingulate cortex.25 ANT was thought to be a suitable target given its wide
connections throughout the brain, especially with those circuits
related to epilepsy.
The pivotal multicenter double-blind RCT of stimulation of
the anterior nucleus of the thalamus in epilepsy (SANTE) included 110 adult patients with medically refractory (failing greater
than 2 antiepileptic drugs), partial-onset epilepsy.26 Sixty percent
of patients had temporal-onset seizures, 27.3% had frontal-onset,
and remainder of seizure onsets included diffuse/multifocal/others
(18.2%), parietal (4.5%), and occipital (4.5%). The main clinical
end points were safety as deﬁned by adverse events/sudden
unexpected death in epilepsy events and efﬁcacy as deﬁned by
the seizure rate between active and control stimulations using
generalized estimating equations. Secondary end points were
responder (>50% seizure reduction) rate, seizure-free interval,
mean percentage of seizure-free days, and treatment failure rate.
Quality of life was also measured (using QOLIE-31), as well as
neuropsychological testing, rescue medication use, and healthcare
resources utilization. Subjects had an average of 6 or more partialonset seizures per month and were refractory to at least 3 antiepileptic drugs. The parallel-arm study design was as follows:
3-month baseline phase, 1-month operative, 3-month blinded,
9-month unblinded, and long-term follow-up (Figure). When
patients were randomized in a 1:1 fashion, investigators observed a
17% decrease in total seizure rate in the blinded active (5 V) vs
control (0 V) groups by post hoc analysis (P = .045) and a 38%
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21% decrease in frequency of focal seizures with impaired
awareness from baseline rates in active stimulation compared with
baseline (P = .038), but not signiﬁcant compared with the control
stimulation group, in a 6-month blinded phase. When both
groups were stimulated for 6 months in an unblinded phase, a
combined 20% decrease in seizure frequency from baseline was
observed (P = .009).28 It was terminated early because of the lack
of the beneﬁcial effect. Limitations of the study included small
sample sizes and short period of observation.
On the basis of these studies, including the long-term followup, the FDA approved ANT DBS for the treatment of focal-onset
epilepsy with or without secondary generalization in 2018.29

FIGURE. Study design of the stimulation of the anterior nucleus of the
thalamus in epilepsy trial. Reproduced with permission from Fisher et al,26
Wiley Periodicals, Inc. © 2010 International League against epilepsy.

decrease in median seizure frequency at 3 months of active stimulation compared with 14.5% with sham stimulation. Across the
entire blinded phase, the median seizure frequency was decreased by
35% with active stimulation and 21.1% with control stimulation
(P = .119). Four months after DBS implantation, all patients had
active stimulation with programing restrictions and antiepileptic
drugs stability as an open-label unblinded phase (3-9 months after
implant). There were no such restrictions in longer-term follow-up in
the past 9 months after implant. Seizure frequency was progressively
reduced with a longer duration of use; median seizure frequencies for
years 1 to 7 were as follows: 41.1%, 55.6%, 52.9%, 65.9%,
69.4%, 74.9%, and 74.8%. At 2 years of open-label use,
53.7% of patients had >50% decrease in seizure frequency (“responders”),26 67.8% responder rate was observed after a total of
5 years of open-label use,27 and at 7 years, 74% of patients were
responders.27 Quality of life as measured by the Liverpool Seizure
Severity Score and QoLIE-31 showed statistically-signiﬁcant and
clinically-meaningful improvement carrying out to 5 years of ANT
stimulation.27 The SANTE trial and its follow-up results are notable
in the context of their low dropout rate, with 75 of 110 implanted
subjects remaining active beyond 5 years.27
A smaller RCT, designed in the same manner as SANTE,
performed in 18 patients with severe and refractory forms of
epilepsy (averaging 43.5 impaired awareness and 9.6 generalized
tonic-clonic seizures per month) from a single center showed a
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Safety of DBS Surgery
Although DBS is an invasive procedure, extensive collective
experience and follow-up with DBS, including its long history of
use in movement disorders, have shown it to be very safe. The
predominant risks are surgical site infections (9%-12%) and
intracranial hemorrhage (1.6%-3.7%).30 Less adverse risks include lead migration (1.6%) or fracture (1.5%), skin erosion
(0.48%), paresthesias, and generator malfunction.31 Rarely reported complications include wire-tethering strictures,32 aborted
procedures, or deaths. Potential complications speciﬁc to anterior
thalamic nucleus DBS, discussed further below, include possible
worsening of a mood disorder or depression.
Systematic Reviews
Multiple literature reviews of RCTs and case series regarding
DBS for epilepsy show a steady increase in the use of DBS as a
neurostimulation strategy and support its use for medically refractory epilepsy.33-39 Previous systematic reviews have noted the
lack of studies with direct comparisons between neurostimulation
strategies.40 Three rigorous systematic reviews of interest support
the use of ANT DBS in medically refractory epilepsy. Chambers
and Bowen41 evaluated 11 studies regarding electrical stimulation
for medically-refractory epilepsy, including 6 RCTs for DBS and
VNS. They noted the reduced seizure frequency with ANT DBS,
especially with long-term use. The authors did not comment on
the potential reporting bias because seizure reporting is reliant on
self-reporting and risk of publication bias based on incomplete
reporting of all outcomes. The Cochrane Group performed a
systematic review of 12 RCTs of neurostimulation for refractory
epilepsies including DBS and RNS.30 Based on the SANTE RCT,
they concluded that ANT DBS was safe and well tolerated, with
high-quality evidence suggesting that 3 months of ANT DBS
reduced seizure frequency, despite the potential reporting bias.
They noted no signiﬁcant impact on seizure freedom or responder
rate.30 Boon et al42 included a systematic review of all available
invasive and noninvasive neurostimulation techniques (including
VNS, DBS, RNS, transcranial direct current stimulation,
transcutaneous VNS, TMS, and trigeminal nerve stimulation).
For ANT DBS, they evaluated the SANTE RCT and the 2
previous systematic reviews; they summarized the previous reviews
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as suggesting low-moderate quality evidence for the safety and efﬁcacy
of ANT DBS for refractory epilepsies. Added review of literature
suggested no contraindications to ANT DBS except to caution the
potential increase in self-reported mood or memory issues.
Noncomparative Studies
Numerous open-label studies and case series since the ﬁrst
human reports for ANT DBS in the 1980s43 show efﬁcacy
ranging from 24% to 90% seizure frequency reduction in generalized, focal, and secondarily generalized seizures (previously
reviewed extensively25,44). The use of ANT DBS has been additionally reported in Dravet syndrome,45 refractory status epilepticus,46 and in patients with epilepsy refractory to VNS
therapy.47 The ﬁrst notable modern case series was an open-label
study of 5 patients with refractory epilepsy implanted in bilateral
ANT in which Hodaie et al48 showed a 54% seizure frequency
reduction with a 15-month average follow-up and Kerrigan et al49
found 4/5 patients with a clinically signiﬁcant seizure frequency
reduction, especially of secondarily generalized and seizures with
impaired awareness. However, it should be noted that reductions
in seizure frequency were not signiﬁcant when pooled across all
patients in this series, indicating the intersubject variability. Lee
et al50 published a larger series of 15 patients and reported a 70%
reduction in seizure frequency with a 27-month average followup. Oh et al51 showed improved neuropsychological scores in
verbal ﬂuency and verbal memory in 9 ANT DBS patients after
1 year of therapy and an average seizure reduction of 57.9%. A
single-center retrospective study of 29 consecutive patients
over 11 years showed 62% to 80% seizure frequency reduction
with a 70-month median follow-up. In contrast to SANTE,
this group did not note a trend to progressive efﬁcacy with the
reduction in either the seizure frequency or the responder rate
with continuous use.52 The variability in seizure frequency
reduction among patients may be an innate characteristic of the
underlying network such as functional connectivity between
the ANT and the default mode network53 and remains under
investigation. ANT-DBS has been considered in a recent
Delphi consensus statement.54 They note that although many
technical facets of ANT-DBS remain under investigation, such
as the timing of turning on the stimulator and trajectory, the
efﬁcacy of ANT-DBS has been consistently shown.54 Favorable
outcomes with a lower side effect proﬁle have been localized to
the anterior–superior portion of the anterior nucleus,55,56
targeting the junction of the ANT-MTT border,57 and
proximity to the wall of the lateral ventricle.58
Targeting
Appropriate targeting methods are of importance in considering ANT-DBS. Targeting has evolved from coordinate-based
systems to the use of electrophysiology vs poor-quality imaging
techniques and most recently direct targeting with higher ﬁeld
MRI and improved image quality. Direct targeting includes the
use of speciﬁc MRI sequences such as Fast Gray Matter
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Acquisition T1 Inversion Recovery (FGATIR).59 Direct targeting
was shown to be superior to microelectrode recording of ANT,60,61
speciﬁcally when targeting the anteroventral thalamus.62 Although neurophysiological measures such as driving response
have been shown to have limited utility in deriving correct
placement,63,64 different spiking patterns have been found in
different areas of ANT,65 suggesting a potential future utility.
Hand-in-hand with targeting methods, a variety of trajectories
have been shown to be efﬁcacious for ANT, including the most
common transventricular trajectory 66 and less common
transcortical, posterior,67 and parietal extraventricular trajectories.68 An observational database study showed that a
transventricular trajectory was more likely to provide accurate
electrode placement within the ANT target, with 90% of
electrodes having at least 1 electrode in ANT, as compared with
79% in extraventricular trajectories.66
Adverse Events
There have been some reports of worsened mood disorders,
depression, and memory impairments with ANT-DBS; however,
the long-term follow-up of the SANTE trial did not ﬁnd a signiﬁcant association between ANT-DBS and worsened mood
disorders.69 There are some case series data that have suggested
neuropsychological and cognitive effects with chronic ANT
stimulation, including decreased response inhibition,70 sleep
disruption,71 and psychiatric adverse effects72 perhaps related to
ANT interaction with the vigilance networks.73

CONCLUSIONS AND FUTURE DIRECTIONS
DBS is a safe and effective neuromodulatory strategy to reduce
seizure frequency in medically refractory causes of epilepsies. Patient
selection and surgical and stimulation strategies are best performed
by a multidisciplinary team of experts, including neurosurgeons and
epileptologists, with patient input. RCT evidence suggests that, in
appropriate and carefully selected patients with focal-onset epilepsy,
with or without secondary generalization, DBS can modulate seizure
networks to result in a progressive reduction in seizure frequency.
Future and ongoing investigations include stimulation of other brain
areas,74 improvement in peri-ictal consciousness,75,76 and DBS in
pediatric populations suffering epilepsies.77,78
Funding
This study did not receive any funding or ﬁnancial support. Dr Schwalb has
research funding from Medtronic. Dr Niemat and Dr Englot have funding
from NIH.

Disclosures
Dr Wu is a consultant for Medtronic, Inc; Abbott; Boston Scientiﬁc, Corp; and
NeuroPace, Inc. Dr Gerrard is a consultant for Medtronic; Boston Scientiﬁc, Corp;
and Longevity Neuro Solutions. Dr Niemat is a consultant for Medtronic. The
other authors have no personal, ﬁnancial, or institutional interest in any of the
drugs, materials, or devices described in this article.

VOLUME 90 | NUMBER 5 | MAY 2022 | 639

© Congress of Neurological Surgeons 2022. Unauthorized reproduction of this article is prohibited.

GUMMADAVELLI ET AL

REFERENCES
1. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a
systematic review and meta-analysis of international studies. Neurology. 2017;88(3):
296-303.
2. Kwan P, Brodie MJ. Early identiﬁcation of refractory epilepsy. N Engl J Med. 2000;
342(5):314-319.
3. Kwan P, Arzimanoglou A, Berg AT, et al. Deﬁnition of drug resistant epilepsy:
consensus proposal by the ad hoc task force of the ILAE commission on therapeutic
strategies. Epilepsia. 2010;51(6):1069-1077.
4. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and incidence of
drug-resistant mesial temporal lobe epilepsy in the United States. World Neurosurg.
2017;99:662-666.
5. Nei M, Bagla R. Seizure-related injury and death. Curr Neurol Neurosci Rep. 2007;
7(4):335-341.
6. England MJ, Liverman CT, Schultz AM, Strawbridge LM. Epilepsy across the
spectrum: promoting health and understanding. A summary of the Institute of
Medicine report. Epilepsy Behav. 2012;25(2):266-276.
7. Engel J Jr, Wiebe S, French J, et al. Practice parameter: temporal lobe and localized
neocortical resections for epilepsy: report of the Quality Standards Subcommittee of
the American Academy of Neurology, in association with the American Epilepsy
Society and the American Association of Neurological Surgeons. Neurology. 2003;
60(4):538-547.
8. Wiebe S, Blume WT, Girvin JP, Eliasziw M. Effectiveness, Efﬁciency of Surgery for
Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for
temporal-lobe epilepsy. New Engl J Med. 2001;345(5):311-318.
9. Andrews JP, Gummadavelli A, Farooque P, et al. Association of seizure spread with
surgical failure in epilepsy. JAMA Neurol. 2019;76(4):462-469.
10. Spencer S, Huh L. Outcomes of epilepsy surgery in adults and children. Lancet
Neurol. 2008;7(6):525-537.
11. Englot DJ, Wang DD, Rolston JD, Shih TT, Chang EF. Rates and predictors of
long-term seizure freedom after frontal lobe epilepsy surgery: a systematic review
and meta-analysis. J Neurosurg. 2012;116(5):1042-1048.
12. Tellez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following
epilepsy surgery: a systematic review and meta-analysis. Brain. 2005;128(pt 5):
1188-1198.
13. de Tisi J, Bell GS, Peacock JL, et al. The long-term outcome of adult epilepsy
surgery, patterns of seizure remission, and relapse: a cohort study. Lancet. 2011;
378(9800):1388-1395.
14. Wu C, Jermakowicz WJ, Chakravorti S, et al. Effects of surgical targeting in laser
interstitial thermal therapy for mesial temporal lobe epilepsy: a multicenter study of
234 patients. Epilepsia. 2019;60(6):1171-1183.
15. Gross RE, Stern MA, Willie JT, et al. Stereotactic laser amygdalohippocampotomy
for mesial temporal lobe epilepsy. Ann Neurol. 2018;83(3):575-587.
16. Ahmad S, Khanna R, Sani S. Surgical treatments of epilepsy. Semin Neurol. 2020;
40(6):696-707.
17. Wu C, Schwalb JM, Rosenow J, McKhann G II, Neimat J. American Society for
Stereotactic and Functional Neurosurgeons. American Society for Stereotactic and
Functional Neurosurgery position statement on laser interstitial thermal therapy for
the treatment of drug-resistant epilepsy. Neurosurgery. 2022;90(2):155-160.
18. The Vagus Nerve Stimulation Study Group. A randomized controlled trial of
chronic vagus nerve stimulation for treatment of medically intractable seizures.
Neurology. 1995;45(2):224-230.
19. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy
for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51(1):
48-55.
20. Morris GL III, Mueller WM. Long-term treatment with vagus nerve stimulation in
patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01E05. Neurology. 1999;53(8):1731-1735.
21. Morrell MJ. Group RNSSiES. Responsive cortical stimulation for the treatment of
medically intractable partial epilepsy. Neurology. 2011;77(13):1295-1304.
22. Heck CN, King-Stephens D, Massey AD, et al. Two-year seizure reduction in
adults with medically intractable partial onset epilepsy treated with responsive
neurostimulation: ﬁnal results of the RNS system pivotal trial. Epilepsia. 2014;
55(3):432-441.
23. Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efﬁcacy and safety of
brain-responsive neurostimulation for focal epilepsy. Neurology. 2020;95(9):
e1244-e1256.

640 | VOLUME 90 | NUMBER 5 | MAY 2022

24. Parisi V, Lundstrom BN, Kerezoudis P, Alcala zermeno JL, Worrell GA, van
Gompel JJ. Anterior nucleus of the thalamus deep brain stimulation with concomitant vagus nerve stimulation for drug-resistant epilepsy. Neurosurgery. 2021;
89(4):686-694.
25. Child ND, Benarroch EE. Anterior nucleus of the thalamus: functional organization and clinical implications. Neurology. 2013;81(21):1869-1876.
26. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of
thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51(5):899-908.
27. Salanova V, Witt T, Worth R, et al. Long-term efﬁcacy and safety of thalamic
stimulation for drug-resistant partial epilepsy. Neurology. 2015;84(10):
1017-1025.
28. Herrman H, Egge A, Konglund AE, Ramm-Pettersen J, Dietrichs E, Taubøll E.
Anterior thalamic deep brain stimulation in refractory epilepsy: a randomized,
double-blinded study. Acta Neurol Scand. 2019;139(3):294-304.
29. FDA. Premarket Approval (PMA) for Medtronic DBS Therapy for Epilepsy. 2018.
Accessed June 11, 2021. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/
cfpma/pma.cfm?id=P960009S219.
30. Sprengers M, Vonck K, Carrette E, Marson AG, Boon P. Deep brain and cortical
stimulation for epilepsy. Cochrane Database Syst Rev. 2017;7(7):CD008497.
31. Jitkritsadakul O, Bhidayasiri R, Kalia SK, Hodaie M, Lozano AM, Fasano A.
Systematic review of hardware-related complications of deep brain stimulation: do
new indications pose an increased risk? Brain Stimul. 2017;10(5):967-976.
32. Miller PM, Gross RE. Wire tethering or ‘bowstringing’ as a long-term hardwarerelated complication of deep brain stimulation. Stereotact Funct Neurosurg. 2009;
87(6):353-359.
33. Ooi YC, Styliaras JC, Sharan A. Thalamic stimulation for epilepsy. Neurosurg Clin
N Am. 2011;22(4):457-464, v-vi.
34. Salanova V. Deep brain stimulation for epilepsy. Epilepsy Behav. 2018;88S:21-24.
35. Kwon CS, Ripa V, Al-Awar O, et al. Epilepsy and neuromodulation-randomized
controlled trials. Brain Sci. 2018;8(4):69.
36. Klinger N, Mittal S. Deep brain stimulation for seizure control in drug-resistant
epilepsy. Neurosurg Focus. 2018;45(2):E4.
37. Zhou JJ, Chen T, Farber SH, Shetter AG, Ponce FA. Open-loop deep brain
stimulation for the treatment of epilepsy: a systematic review of clinical outcomes
over the past decade (2008-present). Neurosurg Focus. 2018;45(2):E5.
38. de Oliveira T, Cukiert A. Deep brain stimulation for treatment of refractory
epilepsy. Neurol India. 2020;68(suppl):S268-S277.
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60. Möttönen T, Katisko J, Haapasalo J, et al. Deﬁning the anterior nucleus of the
thalamus (ANT) as a deep brain stimulation target in refractory epilepsy: delineation using 3 T MRI and intraoperative microelectrode recording. Neuroimage
Clin. 2015;7:823-829.
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